Latest News and Press Releases

The paper in STTT concludes that orelabrutinib significantly prolongs PFS and reduces the risk of disease progression or death by 68%.

Orelabrutinib is the first BTK inhibitor globally to demonstrate efficacy in a Phase II clinical trial for SLE.

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.

Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional...

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...

Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.

Pune, India, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coronary stents are a kind of little mesh metal tubes that are developed for providing support to the weakened arteries within the heart. The coronary...